BioCentury | Jul 25, 2019
Company News

As Vertex broadens remit, Leiden handing baton to Kewalramani

...development for the bone therapeutic area. Vertex slipped $3.78 to $169.56 Thursday. Elizabeth S. Eaton, Staff Writer Kalydeco, ivacaftor (VX-770) Orkambi...
BioCentury | Jun 5, 2019
Company News

U.K. parents form group to buy generic versions of Vertex CF drugs

...in developing these medicines and the overall biotech sector in the UK." Elizabeth S. Eaton, Staff Writer Kalydeco, ivacaftor (VX-770) Orkambi...
BioCentury | May 23, 2019
Company News

Impasse over Vertex CF drugs likely to continue despite NHS’s managed access offer

...free cystic fibrosis drugs to “patients who are the most seriously ill.” Elizabeth S. Eaton, Staff Writer Kalydeco, ivacaftor (VX-770) Orkambi...
BioCentury | May 17, 2019
Product Development

Abeona tackles gene therapy’s problems in cystic fibrosis with chimeric AAVs

As it builds up its preclinical pipeline, Abeona is switching gears to create chimeric AAV vectors that it hopes will do a better job than naturally occurring ones of dialing in the right properties for...
BioCentury | May 1, 2019
Company News

April 30 Company Quick Takes: Merck, G1, Pfizer, Amgen and more

...trastuzumab. BioCentury Staff Aimovig, erenumab-aooe (AMG 334) Erleada (Brand), JNJ56021927 (Compound #), ARN-509 (Compound #), apalutamide (Generic), Erleada (Other) Kalydeco, ivacaftor (VX-770) Mavyret...
BioCentury | Dec 21, 2018
Company News

U.K. committee releases Orkambi documents; pricing details lacking

...similar developments across the whole U.K." Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), Boston, Mass. Business: Pulmonary Elizabeth S. Eaton Kalydeco, ivacaftor (VX-770) Orkambi...
BioCentury | Dec 20, 2018
Company News

U.K. committee releases Orkambi documents; pricing details lacking

...see similar developments across the whole U.K." Vertex added $2.64 to $161.30 on Thursday. Elizabeth S. Eaton Kalydeco, ivacaftor (VX-770) Orkambi...
BioCentury | Nov 10, 2018
Company News

U.K. Parliament issues ultimatum to Vertex, NHS, NICE

...U.K. Government to Resolve Orkambi Impasse" ). Vertex added $0.29 to $180.55 on Friday. Elizabeth S. Eaton Kalydeco, ivacaftor (VX-770) Orkambi...
BioCentury | Nov 2, 2018
Clinical News

EC approves Symkevi, Kalydeco combination for cystic fibrosis

...molecule potentiator of CFTR. Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), Boston, Mass. Product: Symkevi tezacaftor/ivacaftor Business: Pulmonary Alicia Parker Kalydeco, ivacaftor (VX-770) Symdeko...
BioCentury | Oct 12, 2018
Clinical News

Combinations of CF correctors from McGill could rescue more mutations

...Quebec Product: Cystic fibrosis transmembrane conductance regulator (CFTR) correctors Business: Pulmonary Indication: Treat CF Elizabeth S. Eaton Kalydeco, ivacaftor (VX-770) lumacaftor...
Items per page:
1 - 10 of 79